Editorial Perspectives On Decentralized Trials

  1. Tufts Finds Substantial Net Benefits To Using Decentralized Trials 7/28/2022

    For years, vendors have touted decentralized clinical trials (DCTs) as a solution to both the time and cost challenges. DCTs also promise to make trials more patient centric. Unfortunately, a demonstration of the actual benefits of DCTs, along with a quantifiable dollar amount, have been difficult to produce. Until now.

  2. CVS Health Wants To Be Your New Clinical Research Site 7/6/2022

    CVS has been a well-regarded and recognized healthcare brand that started as a pharmacy but has since migrated into a recognized and trusted healthcare company. Now CVS is hoping to expand the relationship it has with patients by moving closer into primary care and clinical trials.

  3. What Does The Future Hold For Decentralized Clinical Trials? 4/20/2022

    What can we expect to see from decentralized trials in the next three years, and what are the challenges sponsor companies will need to overcome? A webinar hosted by IBM Watson hoped to answer that question and many others.

  4. The Next Three Years Of Clinical Trials: DCTs, RWE, And Beyond 4/18/2022

    Recent years have seen unprecedented innovation in the clinical space. Precision medicine, cell and gene therapies, decentralized trials, real-world data, and the promise of artificial intelligence (AI) and machine learning (ML) are just a few of the reasons to be excited about the future of clinical research.

  5. Trends To Watch In 2022: RWD, DCTs, And Cell & Gene Trials 12/16/2021

    As we prepare to close out 2021 and look ahead to 2022, it’s a good time to think about the trends that will impact clinical trials in the new year. At this time of year, I receive numerous emails from companies outlining predictions for the coming year from some of their executives. Here are a few I'd like to share.

  6. Report: Hybrid Clinical Trials Are Here To Stay 11/4/2021

    ISR Reports has released a new report titled Hybrid/Virtual/Decentralized Clinical Trials Market Outlook. The report looks at the adoption of these trials and the components that are gaining the most traction.

  7. Decentralized Trials Can Overcome The Challenges Of Rare Disease Patients 10/5/2021

    There are 400 million people worldwide who are impacted by more than 7,000 identifiable rare diseases. While individual rare diseases are uncommon, approximately 5% of the world’s population suffers from one. A new report from technology provider THREAD details how many of the clinical challenges posed by rare disease trials can be alleviated by decentralized trials.

  8. Can Smarter Study Design Relieve The Recruitment Challenge? 9/18/2021

    Recruitment has always been a challenge for companies conducting clinical trials. Sponsor companies seeking new ways to engage and recruit patients have seen varied success. But could that challenge be mitigated or eliminated with smarter study design?

  9. Traditional Trials Are Dead – Virtual Trials Are The Future 9/3/2021

    It’s no secret that decentralized clinical trials, also known as virtual trials, are one of the hottest technology trends in the clinical space. Although this trial model has been touted by vendors for many years, it took the emergence of the COVID-19 pandemic in 2020 to get many companies scrambling to implement the new approach.

  10. How Otsuka Uses Decentralized Trials & Real-World Evidence 8/3/2021

    Prior to joining Otsuka in 2019, Christoph Koenen spent two years with GSK, 10 years with Novo Nordisk, and eight years with BMS. I recently spoke to him about some of the key lessons he’s learned over the years and how Otsuka is applying new clinical trial strategies and technologies, especially for the treatment of patients in mental health trials.